Aurobindo Pharma Ltd Share Price
(AUROPHARMA)
₹1176.35▲1.6%
as on 04:01PM, 03 Apr 2025
🔔 Market Surge Alert
Aurobindo Pharma shares surged over 7% after the U.S. exempted pharmaceuticals from reciprocal tariffs, benefiting the company's significant U.S. revenue exposure.
Aurobindo Pharma Performance
Day's Low
Day's High
₹1,173.05Day's Price Range₹1,267.352 Week's Low
52 Week's High
₹1,031.0552-Week Price Range₹1,592
| Returns % | |
| 1 Month Return | + 8.97 % |
| 3 Month Return | -12.25 % |
| 1 Year Return | + 1.78 % |
| Market Stats | |
| Previous Close | ₹1,157.85 |
| Open | ₹1,229.00 |
| Volume | 75.02L |
| Upper Circuit | ₹1,273.60 |
| Lower Circuit | ₹1,042.10 |
| Market Cap | ₹67,842.90Cr |
Aurobindo Pharma Fundamentals
P/E Ratio
19.38
PEG Ratio
1.55
Market Cap
₹67,842.90 Cr
P/B Ratio
3.24
EPS
54.09
Dividend Yield
0.41
Sector
Pharmaceuticals
ROE
10.35
Mutual Fund Holdings of Aurobindo Pharma
Aurobindo Pharma Analyst Rating
based on 28 analysts
78.57%
Buy
7.14%
Hold
14.29%
Sell
Based on 28 analysts offering long term price targets for Aurobindo Pharma. An average target of ₹1483.14
Source: S&P Global Market Intelligence
Aurobindo Pharma Share analysis
Aurobindo Pharma price forecast by 28 analysts
Upside of28.09%
High
₹1930
Target
₹1483.14
Low
₹1140
Aurobindo Pharma target price ₹1483.14, a slight upside of 28.09% compared to current price of ₹1176.35. According to 28 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Aurobindo Pharma revenue growth forecast
Expected growth rate Q1, FY2027:28.51%
Forecast
Actual
Including amortisation and stock based compensations
Aurobindo Pharma EPS growth forecast
EPS estimate Q1, FY2027:51.50%
Forecast
Actual
Source: S&P Global Market Intelligence
What's happening today
Today's Timeline - Invalid Date
05:30 AM
-Aurobindo Pharma shares surged 7.36% after U.S. exempted pharmaceuticals from new reciprocal tariffs.
Key events for Aurobindo Pharma Ltd
Aurobindo Pharma Shares Surge After Tariff Exemption - 03 Apr, 2025
Aurobindo Pharma's stock jumped 7.36% on April 3, 2025, following the U.S. administration's exemption of pharmaceuticals from reciprocal tariffs, benefiting the company's significant U.S. revenue exposure.Aurobindo Pharma Faces Potential Tariff Challenges - 02 Apr, 2025
Aurobindo Pharma may experience margin pressure due to potential tariffs of up to 35% on exports, affecting its substantial revenue from the US market.Curateq Biologics Issues CCPS to Dr. Makkapati - 21 Mar, 2025
Curateq Biologics, a subsidiary of Aurobindo Pharma, allotted 4,125,055 Compulsory Convertible Preference Shares to Dr. Satakarni Makkapati, resulting in a 2% equity stake. This will change Curateq's status from a wholly owned subsidiary to a subsidiary of Aurobindo Pharma.Aurobindo Pharma Faces Challenges Amid Expansion Efforts - 20 Mar, 2025
Aurobindo Pharma's stock has dropped 13% in 2025 due to slow US approvals and upcoming patent expirations. The company is expanding capacity and product lines, investing $300 million in a new Pen-G facility. Despite achieving record quarterly revenue, net profit declined due to foreign exchange losses. Elara Securities maintains a buy rating with a target price of ₹1,568, indicating a potential upside.Aurobindo Pharma Receives VAI Status, Shares Rise - 19 Mar, 2025
Aurobindo Pharma's Apitoria Pharma Unit V received a Voluntary Action Indicated classification from the US FDA, boosting investor confidence and share prices. Despite a decline in net profit, revenue increased year-on-year.Aurobindo Pharma Expands Biosimilars and Diversification Plans - 13 Mar, 2025
Aurobindo Pharma's CuraTeq Biologics aims to launch 10 biosimilars by 2031. The company emphasizes diversification and expansion to sustain profitability amid global challenges.Aurobindo Pharma Terminates Vaccine License Agreement - 05 Mar, 2025
Aurobindo Pharma has terminated its license agreement with Hilleman Laboratories for a pentavalent vaccine candidate, emphasizing that this decision will not materially affect its operations or financials.
Insights on Aurobindo Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 6.46% to 6.69% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 10 quarters, 5.79K Cr → 8.13K Cr (in ₹), with an average increase of 3.7% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 817.38 Cr → 845.81 Cr (in ₹), with an average increase of 3.4% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 126.6% return, outperforming this stock by 59.4%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 53.8% return, outperforming this stock by 52.0%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 51.82% of holdings in Dec 2024 quarter
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 18.53% to 17.81% in Dec 2024 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 16.59% to 16.29% in Dec 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 7 days, AUROPHARMA stock has moved down by -0.6%
Aurobindo Pharma News
Pharma Stocks Surge 7% After Trump Exempts Pharmaceuticals from Tariffs
Shares of Pharmaceutical companies on Thursday climbed 7 per cent after the Trump administration exempted pharmaceuticals from reciprocal tariffs. Aurobindo Pharma by 1.50 per cent to finish at Rs 1,176.05.03 Apr, 2025 06:30 PMPharma Stocks Face Uncertainty Amid Trump Tariffs
HDFC Securities in a note said that Aurobindo Pharma will be the worst impacted. Among the domestic companies, Aurobindo Pharma's proportion of US sales versus their overall sales, are highest at 46%.03 Apr, 2025 03:17 PMPharma Stocks to Keep in Portfolio Amid US Tariff Challenges
Assuming a baseline 10 per cent tariff cost, in our bear case scenario (40 per cent cost absorption), we see a 1-2 per cent adverse impact on our FY27E Ebitda, with Aurobindo Pharma seeing the highest impact.03 Apr, 2025 01:04 PMAurobindo Pharma Financials
Aurobindo Pharma Index Inclusions
Aurobindo Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.82% | 0.00 | |
| Foreign Institutions | 16.29% | ||
| Mutual Funds | 17.81% | ||
| Retail Investors | 6.69% | 3.51 | |
| Others | 7.4% | 11.99 |
Aurobindo Pharma Key Indicators
Aurobindo Pharma Valuation
Aurobindo Pharma in the last 5 years
Lowest (6.73x)
March 23, 2020
Today (19.38x)
April 2, 2025
Industry (52.26x)
April 2, 2025
Highest (27.59x)
December 21, 2023
Aurobindo Pharma Earnings and Dividends
Aurobindo Pharma Ltd Earnings Results
Aurobindo Pharma Ltd’s net profit fell -9.66% since last year same period to ₹845.81Cr in the Q3 2024-2025. On a quarterly growth basis, Aurobindo Pharma Ltd has generated 3.48% jump in its net profits since last 3-months.
Read More about Earnings ResultsAurobindo Pharma Ltd Dividends February,2024
In the quarter ending December 2023, Aurobindo Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.38%.
Read More about Dividends
Aurobindo Pharma Technicals Summary
Bearish
Neutral
Bullish
Aurobindo Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
Aurobindo Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹67,842.90 Cr | 40.56% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| BUY | ₹13,532.31 Cr | -2.34% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| HOLD | ₹89,670.54 Cr | 44.91% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹62,774.41 Cr | 17.37% | 0.53 | NA | NA | |
| BUY | ₹47,037.28 Cr | 25.36% | 0.56 | ₹589 Cr | ₹3,453 Cr |
About Aurobindo Pharma
The company is well known for its top products such as antibiotics, anti-malarials, cardiovascular, and anti-diabetic drugs. Its popular brands include Aurolife, Aurocare, Aurochem, and Aurovit. Aurobindo Pharma is one of the largest manufacturers of generic drugs in India, with a presence in over 150 countries worldwide.
Revenue: ₹7,893.15Cr as on December 2024 (Q4 24)
Net Profit: ₹845.57Cr as on December 2024 (Q4 24)
Listing date: 19 Oct, 1995
Chairperson Name: K Ragunathan
| Organisation | Aurobindo Pharma |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Aurobindo Pharma Ltd
What is Aurobindo Pharma Ltd price today?
Aurobindo Pharma Ltd share price today stands at ₹1176.35, Open: ₹1229, Previous Close: ₹1157.85, High: ₹1267.3, Low: ₹1173.05, 52 Week High: ₹1592, 52 Week Low: ₹1031.05.
How to Buy Aurobindo Pharma Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Aurobindo Pharma Ltd shares
What are today's traded volumes of Aurobindo Pharma Ltd?
Today's traded volume of Aurobindo Pharma Ltd(AUROPHARMA) is 75.02L.
What is today's market capitalisation of Aurobindo Pharma Ltd?
Today's market capitalisation of Aurobindo Pharma Ltd(AUROPHARMA) is ₹67842.9Cr.
What is the 52 Week High and Low Range of Aurobindo Pharma Ltd?
How much percentage Aurobindo Pharma Ltd is down from its 52 Week High?
Aurobindo Pharma Ltd (AUROPHARMA) share price is ₹1176.35. It is down -26.11% from its 52 Week High price of ₹1592
How much percentage Aurobindo Pharma Ltd is up from its 52 Week low?
Aurobindo Pharma Ltd (AUROPHARMA) share price is ₹1176.35. It is up 14.09% from its 52 Week Low price of ₹1031.05